Pharmaxis has announced results from its Phase II trial in patients with cystic fibrosis. The trial achieved its primary end point of improvement in lung function.
At the end of two-week treatment periods, patients receiving Bronchitol had significantly improved lung function compared to patients receiving two weeks of placebo treatment.
The study was a double-blind, placebo-controlled, randomized comparison of
420 mg of Bronchitol to placebo in 49 patients with cystic fibrosis at eight centers across Australia and New Zealand. Bronchitol or placebo was administered twice a day for 14 days.